Samsung Biologics Publishes Prospectus for PolyPeptide Public Tender Offer
Samsung Biologics' subsidiary Samsung Peptide AG has published a prospectus for a public tender offer for PolyPeptide. The largest individual shareholder has committed to tendering all of its shares.
Samsung Peptide AG, a direct subsidiary of Samsung Biologics, has published the official prospectus for its public tender offer for PolyPeptide shares. This publication follows a pre-announcement of the tender offer made on July 20, 2026.
The largest individual shareholder in PolyPeptide has committed to tendering all of its shares into the offer. This commitment is a significant step towards the completion of the acquisition.
The main offer period is expected to commence shortly after the prospectus publication. Specific dates will be announced separately. The tender offer is aimed at strengthening Samsung Biologics' capabilities in peptide drug development and manufacturing.